Previous Close | 0.0600 |
Open | 0.0500 |
Bid | 0.0000 |
Ask | 0.1600 |
Strike | 12.50 |
Expire Date | 2024-07-19 |
Day's Range | 0.0400 - 0.0600 |
Contract Range | N/A |
Volume | |
Open Interest | 945 |
Shah Capital, which currently owns a near 7.5% stake in Novavax and is its third-largest shareholder, reiterated that the company was "undervalued and continues to suffer from poor profitability". Novavax last year had raised doubts about its ability to remain in business, hurt by manufacturing snags and regulatory hurdles that delayed the entry of its protein-based vaccine to the market. Last month, the top shareholder expressed concerns over mismanagement at the Maryland-based biotech and nominated two of its own candidates for the board.
Hedge fund Shah Capital on Monday urged Novavax shareholders to vote against the re-election of three directors and proposals related to executive compensation, ramping up its efforts for a board shakeup at the COVID-19 vaccine maker. Shah Capital, which currently owns a near 7.5% stake in Novavax and is its third-largest shareholder, reiterated that the company was "undervalued and continues to suffer from poor profitability". Novavax last year had raised doubts about its ability to remain in business, hurt by manufacturing snags and regulatory hurdles that delayed the entry of its protein-based vaccine to the market.
Highlights Novavax’s Massive Untapped Value That it Believes is Being Hindered by an Overly Conservative Board and Management That Clings to Failed Strategies and Have Undermined Stockholder Value Calls for Fresh Perspectives in the Boardroom to Restore Investor Confidence in the Company Files Preliminary Proxy and Urges Stockholders to Vote AGAINST The Re-Election of all Class II Directors and AGAINST The Approval of Three of the Company’s Other Proposals at the Annual Meeting RALEIGH, N.C., Ma